DDInter1335 DDInter1628
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) IRAK1
IRAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) FOXJ3
FOXJ3 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) AKT1
AKT1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) GALE
GALE {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) DYRK1A
DYRK1A {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) IRAK1
IRAK1 {u} (Gene) interacts with {v} (Gene) MAP3K7
MAP3K7 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) regulates {v} (Gene) FOXJ3
FOXJ3 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) FOXJ3
FOXJ3 {u} (Gene) is regulated by {v} (Gene) BMPR2
BMPR2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) SMNDC1
SMNDC1 {u} (Gene) is regulated by {v} (Gene) POLR1C
POLR1C {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Omacetaxine mepesuccinate (Compound) downregulates IRAK1 (Gene) and IRAK1 (Gene) is bound by Ruxolitinib (Compound)
Omacetaxine mepesuccinate (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is bound by Ruxolitinib (Compound)
Omacetaxine mepesuccinate (Compound) upregulates FOXJ3 (Gene) and FOXJ3 (Gene) is upregulated by Ruxolitinib (Compound)
Omacetaxine mepesuccinate (Compound) downregulates AKT1 (Gene) and AKT1 (Gene) is downregulated by Ruxolitinib (Compound)
Omacetaxine mepesuccinate (Compound) upregulates GALE (Gene) and GALE (Gene) is downregulated by Ruxolitinib (Compound)
Omacetaxine mepesuccinate (Compound) upregulates DYRK1A (Gene) and DYRK1A (Gene) is bound by Ruxolitinib (Compound) and DYRK1A (Gene) is upregulated by Ruxolitinib (Compound)
Omacetaxine mepesuccinate (Compound) downregulates IRAK1 (Gene) and IRAK1 (Gene) interacts with MAP3K7 (Gene) and MAP3K7 (Gene) is bound by Ruxolitinib (Compound)
Omacetaxine mepesuccinate (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) regulates FOXJ3 (Gene) and FOXJ3 (Gene) is upregulated by Ruxolitinib (Compound)
Omacetaxine mepesuccinate (Compound) upregulates FOXJ3 (Gene) and FOXJ3 (Gene) is regulated by BMPR2 (Gene) and BMPR2 (Gene) is bound by Ruxolitinib (Compound)
Omacetaxine mepesuccinate (Compound) upregulates SMNDC1 (Gene) and SMNDC1 (Gene) is regulated by POLR1C (Gene) and POLR1C (Gene) is upregulated by Ruxolitinib (Compound)